# A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

> **NCT07739589** · PHASE4 · COMPLETED · sponsor: **Insud Pharma** · enrollment: 28 (actual)

## Conditions studied

- Residual Drug Amount of EE and LNG

## Interventions

- **DRUG:** Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System

## Key facts

- **NCT ID:** NCT07739589
- **Lead sponsor:** Insud Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-25
- **Primary completion:** 2021-11-16
- **Final completion:** 2021-11-16
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-08-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739589, "A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07739589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*